Form 4: Recursion Pharmaceuticals Director, Blake Borgeson, Sells Shares Under 10b5-1 Trading Plan

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock on May 28, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 28, 2024, Blake Borgeson, a director of Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at prices ranging from $8.88 to $9.55, with a weighted average sale price of $9.1677.
• Following the transaction, Borgeson directly owns 7,186,913 shares of Recursion Pharmaceuticals.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate sale price upon request.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a share sale by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment, but rather reports a factual transaction.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned through 10b5-1 trading plans to avoid accusations of trading on material non-public information. The market typically analyzes the size and frequency of such sales to gauge insider sentiment.

Stakeholder Impact

• The sale of shares by a director could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the sale.

Key Dates